Fundz

Oncotelic Therapeutics

Agoura Hills, California, United States · Biotechnology, Healthcare, Health Care

Oncotelic Therapeutics, Inc. is focused on developing innovative therapies for cancer treatment, primarily through the use of immunotherapy. The company's key products include novel therapeutic agents designed to enhance the immune response against tumor cells, with a particular emphasis on maximizing patient outcomes in oncology. Its operations are primarily based in the United States, with plans

Key facts

Headquarters
Agoura Hills, California, United States
Employees
22
Industries
Biotechnology, Healthcare, Health Care
Status
Public (OTLC)
Website
mateon.com
LinkedIn
Company page

Recent activity at Oncotelic Therapeutics

  • : Oncotelic Therapeutics Enters Joint Development Agreement with TechForce Robotics (date Fundz recorded it)
  • : SEC 8-K (8.01):
  • : SEC 8-K (8.01):
  • : SEC 8-K (1.01): On August 3, 2026, Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, resulting in the issuance of a convertible promissory note (the 2026 Pacific Pier Note 2) with a gross principal amount of $178,410. This note is convertible into common stock at a fixed price of $0.06 per share or at a discount to the lowest traded price over a set period. Additionally, the company issued 500,000 commitment shares to Pacific Pier. The note carries a 12% annual interest rate, matures one year from the agreement date, and includes provisions for prepayment and potential events of default, which could accelerate repayment terms. The transaction underscores Oncotelic's ongoing efforts in securing financial backing for its operations, reflecting a strategic push towards strengthening its equity position in the market.
  • : SEC 8-K (8.01): On July 13, 2026, Oncotelic Therapeutics, Inc. presented a corporate presentation to its employees, directors, officers, and advisors. This event was reported under Item 8.01 of Form 8-K, indicating it is considered significant for the stakeholders of the company. The presentation aims to inform key personnel about recent developments and strategic directions of the company. A copy of the Corporate Presentation is attached as Exhibit 99.1 to the filing, indicating a structured communication of corporate policies or updates. This presentation is crucial for ensuring that internal stakeholders are aligned with the company’s objectives moving forward.
  • : SEC 8-K (5.02):
  • : SEC 8-K (1.01):
  • : SEC 8-K (1.01): On May 1, 2026, Oncotelic Inc., a subsidiary of Oncotelic Therapeutics, Inc., completed a Merger Agreement with Lunai Bioworks, Inc. and its subsidiary Merger Sub. This triangular merger resulted in Holdings merging into Merger Sub, which continues as a wholly owned subsidiary of Lunai. In consideration for the merger, Lunai issued 8 shares of Series B Convertible Preferred Stock valued at $20,000,000 to the holders, with Oncotelic receiving 5 shares valued at $12,500,000 and Pelerin Therapeutics receiving 3 shares valued at $7,500,000. The transaction solidifies Oncotelic's position through a strategic acquisition of a multi-jurisdictional patent portfolio from Holdings, which previously had no material liabilities or operations.
  • : SEC 8-K (8.01): On April 16, 2026, Oncotelic Therapeutics, Inc. announced its Annual Results and provided corporate updates through a press release. This event highlights significant developments in the company's operations and financial performance for the year. The announcement is critical for security holders as it may influence investor perceptions and market position. The details of the results and any strategic implications will be elaborated in the press release, which is included as Exhibit 99.1.
  • : SEC 8-K (1.01): On March 31, 2026, Oncotelic Therapeutics, Inc. entered into a Joint Development, Manufacturing, and Licensing Agreement with TechForce Robotics, Inc. The Agreement aims to develop AI-enabled, GMP-compliant robotic systems for pharmaceutical manufacturing, combining TechForce's hardware with Oncotelic's proprietary PDAOAI Platform. Key terms include joint ownership of jointly developed intellectual property and revenue-sharing terms to be negotiated in future agreements. The Agreement includes a termination clause allowing either party to terminate for convenience with 60 days' notice, and it restricts TechForce from licensing jointly developed intellectual property for 12 months after termination without consent. This material agreement is significant for both parties' strategic operations in the pharmaceutical sector.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Oncotelic Therapeutics funding history

DateRoundAmount
Dec 2025Venture$275K
Aug 2020Seed$2.0M
May 2019Venture$27.0M
May 2019Seed$600K
Apr 2018Seed$2.9M

Leadership

  • Vuong Trieu, Executive Officer, Director
  • William Schwieterman, Director
  • Bobby Jr., Director
  • Donald Reynolds, Director
  • Simon Pedder, Director
  • David Chaplin, Executive Officer, Director
  • Saran Saund, Chief Business Officer

Verified email and direct lines for Oncotelic Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Companies similar to Oncotelic Therapeutics

About Oncotelic Therapeutics: questions and answers

What does Oncotelic Therapeutics do?

Oncotelic Therapeutics, Inc. is focused on developing innovative therapies for cancer treatment, primarily through the use of immunotherapy. The company's key products include novel therapeutic agents designed to enhance the immune response against tumor cells, with a particular emphasis on maximizing patient outcomes in oncology. Its operations are primarily based in the United States, with plans

Where is Oncotelic Therapeutics headquartered?

Oncotelic Therapeutics is headquartered in Agoura Hills, California, United States.

How many employees does Oncotelic Therapeutics have?

Oncotelic Therapeutics has about 22 employees.

Has Oncotelic Therapeutics raised funding?

Yes. Fundz has recorded 5 funding events for Oncotelic Therapeutics. The most recent, $275K, was in Dec 2025.

What is the latest news on Oncotelic Therapeutics?

On Apr 2, 2026, Oncotelic Therapeutics Enters Joint Development Agreement with TechForce Robotics

Is Oncotelic Therapeutics a public company?

Yes. Oncotelic Therapeutics is publicly traded under the ticker OTLC.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Oncotelic Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.